ArticleEndocrine2026
Newborn screening for congenital adrenal hyperplasia: a 3 years study embedded in 25 years of regional experience in Italy.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNewborn screening for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17-OHP) is hampered by high false-positive rates, especially in preterm and low birth weight infants. Second-tier strategies aim to improve specificity, but population-based data are limited. The aim was to evaluate CAH screening approach using birth weight-adjusted cut-offs and repeated sampling in a large regional cohort.
methodsWe analyzed data from 90,092 infants screened in Piedmont, Italy (2019-2022). 17-OHP was measured in dried blood spots, with birth weight-adjusted thresholds and repeated sampling when indicated. 17-OHP distributions were examined by birth weight and gestational age, and outcomes assessed via recall rate and confirmed diagnoses.
resultsOf 90.092 infants, 746 were recalled (0.82%), and 119 referred for specialist evaluation. Eight infants were diagnosed with classic salt-wasting CAH and one with non-classical CAH (incidence 1:11.261). 17-OHP concentrations inversely correlated with birth weight, capturing most biological variability. Repeated sampling significantly reduced false positives across all birth weight categories. Gestational age stratification offered no clear advantage over birth weight-based thresholds.
conclusionsBirth weight-based CAH screening effectively lowers false positives while identifying classic CAH. Refining percentile-informed cut-offs, particularly in higher birth weight infants, could further enhance efficiency without compromising safety.
Indexed as
Identifiers
42803878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.